Guilherme S. C. Correia, MD (@guicorreiamd) ranks #46 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 3 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: FLAURA2. This profile quotes their 1 trial post from 2026 word for word, with links to the originals on X.
At a Glance
- 1 posts naming a trial in 2026
- 1 trials discussed by name
- Lung Cancer: US #46 · 3 physicians engaged
This Month
What Guilherme S. C. Correia, MD has posted in the last 30 days. Updated November 10, 2026.
Great alternative in this space! Curious about this strategy after an initial FLAURA2 approach. The 🔑is to test for MET overexpression and amplification (noting that MET overexpression has a different threshold for savolitinib compared to Teliso-V in patients with EGFRwt). https://t.co/mMxktxER2u
Who Amplifies Guilherme S. C. Correia, MD
Physicians who reposted Guilherme S. C. Correia, MD’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #46 | — | 3 | 3 | Full ranking |
What Colleagues Are Saying About Guilherme S. C. Correia, MD
2026 posts by fellow physicians that mention @guicorreiamd, quoted word for word.
Workshop with colleagues @JamesFanWu @guicorreiamd @LukasDelasos @nh_osei @dan_morgen Cecilia Jiang under Tianhong Li and Kenneth O’Byrne #WCLC26 #LCSM https://t.co/XMLu91Ux24
Trials Guilherme S. C. Correia, MD Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| FLAURA2 | 1 | #12 of 25 | Oct 25, 2026 |
Guilherme S. C. Correia, MD on FLAURA2
Great alternative in this space! Curious about this strategy after an initial FLAURA2 approach. The 🔑is to test for MET overexpression and amplification (noting that MET overexpression has a different threshold for savolitinib compared to Teliso-V in patients with EGFRwt). https://t.co/mMxktxER2u
Guilherme S. C. Correia, MD’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Real-time first-line updates in ES-SCLC! Getting closer and closer to a 2yr mOS. Tarlatamab + Durvalumab maintenance improved mOS to 21.1 months compared to 12.7 months with single agent Durva. New standard of care in this space! https://t.co/9kDH9ap8HL